20/20 GeneSystems, Licenses Lung Cancer Blood Test to Ortho-Clinical Diagnostics

January 17 , 2008 - 20/20 GeneSystems, Inc. (“20/20”), a developer of innovative diagnostic products for early disease detection and personalized medicine, announced that it has entered into an agreement with Raritan, N.J., based Ortho-Clinical Diagnostics (“OCD”) to license certain 20/20 intellectual property relating to a blood test for the early detection of lung cancer(...) 20/20 and its collaborators from the University of Kentucky have published study results that showed that its multi-biomarker blood test may be able to detect non-small cell lung cancer (NSCLC) significantly earlier and with better accuracy than CT scans, the most advanced technique in current use for detecting this disease...20/20 GeneSystems' Press Release-